Compare McKesson Corporation (MCK) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs UiPath Inc — how do they compare? McKesson Corporation trades at $824.51 (market cap $97.35B), while UiPath Inc trades at $12.01 (market cap $6.30B). The key difference: McKesson Corporation is far larger — about 15.5× UiPath Inc's market cap, and McKesson Corporation pays a 0.39% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| MCK | PATH | |
|---|---|---|
Market Cap | $97.35B | $6.30B |
Sector | Health | Technology |
52-Week High | $995.69 | $19.29 |
52-Week Low | $659.01 | $9.38 |
Enterprise Value | $101.98B | $5.08B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
UiPath (PATH) trades at $12.26, up 0.91% today, with a bullish technical outlook and strong support at $12. The company shows improving fundamentals, with revenue growing to $1.43B in 2025 and a projected net profit of $327M in 2026. Recent news highlights AI partnerships and agentic automation growth, though Q1 2026 EPS missed expectations.
Outlook is cautiously optimistic with a consensus price target of $13.33, offering ~9% upside. Key opportunities include high gross margins and AI adoption, while risks involve execution on profitability and competitive pressures. Institutional sentiment is mixed with 25% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
